Pages that link to "Q50303715"
The following pages link to Effects of short- and long-term risperidone treatment on prolactin levels in children with autism (Q50303715):
Displaying 50 items.
- Atypical Antipsychotics in Children with Pervasive Developmental Disorders (Q22241426) (← links)
- Antipsychotics in the treatment of autism (Q22241891) (← links)
- What’s new in autism? (Q22252699) (← links)
- The risk of elevated prolactin levels in pediatric patients exposed to antipsychotics for the treatment of schizophrenia and schizophrenia spectrum disorders: protocol for a systematic review and meta-analysis (Q26996493) (← links)
- Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents (Q28252741) (← links)
- An Overview of Autism Spectrum Disorder, Heterogeneity and Treatment Options. (Q30235878) (← links)
- Autism. (Q30404476) (← links)
- First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents (Q33845881) (← links)
- Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study (Q33858314) (← links)
- Aripiprazole in autism spectrum disorders and fragile X syndrome (Q34025492) (← links)
- Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents (Q34056408) (← links)
- Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: A review of the randomized controlled studies (Q34183320) (← links)
- Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger's disorder: a 12-week prospective, open-label study (Q34495483) (← links)
- Some side effects and effcts on physical activity of second-generation antipsychotics: A study in children and adolescents (Q34659629) (← links)
- Hyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone (Q35024279) (← links)
- Prolactin variations during risperidone therapy in a sample of drug-naive children and adolescents. (Q35038921) (← links)
- Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth (Q35128405) (← links)
- Pharmacogenetics of antipsychotic-induced side effects (Q35237129) (← links)
- Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. (Q35572650) (← links)
- Prolactin-related adverse events and change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: A systematic review (Q36186039) (← links)
- Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan (Q36443014) (← links)
- Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents (Q37236402) (← links)
- Possible mechanisms for the skeletal effects of antipsychotics in children and adolescents (Q37247927) (← links)
- Risperidone in the treatment of behavioral disorders associated with autism in children and adolescents (Q37337980) (← links)
- An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder (Q37409074) (← links)
- Pharmacogenetics of D2 dopamine receptor gene in prolactin-secreting pituitary adenomas (Q37636030) (← links)
- Psychopharmacology in autism: An update (Q37804959) (← links)
- Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice (Q37835961) (← links)
- Antipsychotic drug toxicology in children (Q37852719) (← links)
- Psychopharmacology of autism spectrum disorders: a selective review (Q38034655) (← links)
- Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis (Q38092009) (← links)
- Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders (Q38095762) (← links)
- Safety and pharmacokinetics of atypical antipsychotics in children and adolescents (Q38099224) (← links)
- Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences (Q38100267) (← links)
- Aripiprazole: a review of its use in the treatment of irritability associated with autistic disorder patients aged 6-17. (Q38122151) (← links)
- An update on medication management of behavioral disorders in autism (Q38184482) (← links)
- Antipsychotics use in children and adolescents: An on-going challenge in clinical practice (Q38217992) (← links)
- Clinical and pharmacokinetic evaluation of risperidone for the management of autism spectrum disorder (Q38266796) (← links)
- Psychopharmacological interventions in autism spectrum disorder (Q38739577) (← links)
- Pharmacogenomics of autism spectrum disorder (Q39154436) (← links)
- 9-Hydroxyrisperidone-Induced Hyperprolactinaemia in Thai Children and Adolescents with Autism Spectrum Disorder (Q39995440) (← links)
- Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists (Q44387572) (← links)
- Buspirone for autistic disorder in a woman with an intellectual disability (Q46868346) (← links)
- An open-label extension long-term study of the safety and efficacy of aripiprazole for irritability in children and adolescents with autistic disorder in Japan. (Q47615376) (← links)
- Development and Validation of Liquid Chromatography/Tandem Mass Spectrometry Analysis for Therapeutic Drug Monitoring of Risperidone and 9-Hydroxyrisperidone in Pediatric Patients with Autism Spectrum Disorders. (Q47898060) (← links)
- Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study (Q50303584) (← links)
- Improved Socio-Emotional and Behavioral Functioning in Students with Autism Following School-Based Smartglasses Intervention: Multi-Stage Feasibility and Controlled Efficacy Study (Q58708865) (← links)
- Des recommandations probantes pour surveiller l’innocuité des antipsychotiques de deuxième génération chez les enfants et les adolescents (Q59938420) (← links)
- UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder (Q89326546) (← links)
- Pathogenetical and Neurophysiological Features of Patients with Autism Spectrum Disorder: Phenomena and Diagnoses (Q90461518) (← links)